Gain Therapeutics (NASDAQ:GANX – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Gain Therapeutics to post earnings of ($0.19) per share for the quarter.
Gain Therapeutics Trading Up 2.2 %
Shares of GANX opened at $2.34 on Monday. The stock’s 50-day moving average price is $2.23 and its 200 day moving average price is $2.03. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $62.07 million, a price-to-earnings ratio of -2.13 and a beta of 0.14. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $4.10.
Analyst Ratings Changes
A number of brokerages recently commented on GANX. Scotiabank began coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price for the company. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, March 17th. Finally, Roth Mkm reissued a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.20.
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Further Reading
- Five stocks we like better than Gain Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Market Cap Calculator: How to Calculate Market Cap
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
